Cargando…

LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR

BACKGROUND: Lysosomal-associated protein transmembrane-4 beta (LAPTM4B), a novel oncogene, promotes tumorigenesis and may be a potential prognostic biomarker in several cancers. This study was to determine the clinical significance and biological roles of LAPTM4B in lung adenocarcinoma (LAC). METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lu, Meng, Yue, Zhang, Qing-Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444825/ https://www.ncbi.nlm.nih.gov/pubmed/30940109 http://dx.doi.org/10.1186/s12885-019-5506-7

Ejemplares similares

Serum LAPTM4B as a Potential Diagnostic and Prognostic Biomarker for Breast Cancer
por: Wang, Lu, et al.
Publicado: (2022)

LAPTM4B Gene Expression and Polymorphism as Diagnostic Markers of Breast Cancer in Egyptian Patients
por: Shaker, Olfat, et al.
Publicado: (2015)

Overexpression of LAPTM4B-35: A Novel Marker of Poor Prognosis of Prostate Cancer
por: Zhang, Hongtuan, et al.
Publicado: (2014)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
por: Zheng, Hongmei, et al.
Publicado: (2019)

Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis
por: Zhou, Linghui, et al.
Publicado: (2018)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Zhang, Haomin, et al.
Publicado: (2021)

LAPTM4B Allele *2 Is a Marker of Poor Prognosis for Gallbladder Carcinoma
por: Zhai, Guojun, et al.
Publicado: (2012)

LAPTM4B knockdown increases the radiosensitivity of EGFR-overexpressing radioresistant nasopharyngeal cancer cells by inhibiting autophagy
por: Chu, Chu, et al.
Publicado: (2019)

LAPTM4B promotes the progression of nasopharyngeal cancer
por: Su, Qun, et al.
Publicado: (2021)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012)

LAPTM4B*2 allele is associated with the development of papillary thyroid carcinoma in Chinese women
por: Meng, Yue, et al.
Publicado: (2017)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

LAPTM4B: an oncogene in various solid tumors and its functions
por: Meng, Y, et al.
Publicado: (2016)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Transport of LAPTM5 to lysosomes requires association with the ubiquitin ligase Nedd4, but not LAPTM5 ubiquitination
por: Pak, Youngshil, et al.
Publicado: (2006)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Retrospective study of EGFR‐mutant lung adenocarcinoma with bone metastatic clinical features
por: Gu, Liyan, et al.
Publicado: (2022)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

LAPTM4B facilitates tumor growth and induces autophagy in hepatocellular carcinoma
por: Wang, Fei, et al.
Publicado: (2019)

AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity
por: Meng, Yue, et al.
Publicado: (2018)

Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients
por: Li, Sha, et al.
Publicado: (2017)

71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES
por: Mamatjan, Yasin, et al.
Publicado: (2020)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
por: Xu, Hui, et al.
Publicado: (2020)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma
por: Kotowski, Ulana, et al.
Publicado: (2019)

A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B
por: Wakata, Kouki, et al.
Publicado: (2015)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
por: Pathak, Ranjan, et al.
Publicado: (2021)

c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma
por: Min, Weili, et al.
Publicado: (2021)

LAPTM4B-YAP loop feedback amplification enhances the stemness of hepatocellular carcinoma
por: Liao, Jianping, et al.
Publicado: (2023)

Relationship Between LAPTM4B Gene Polymorphism and Susceptibility of Malignant Melanoma in Chinese Patients
por: Zhang, Meng, et al.
Publicado: (2014)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
por: Bai, Lu, et al.
Publicado: (2023)

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
por: Yang, Lei, et al.
Publicado: (2022)

LAPTM4B Allele *2 Is a Marker of Poor Prognosis Following Hepatic Tumor Resection for Hepatocellular Carcinoma
por: Yang, Hua, et al.
Publicado: (2012)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
por: Chiu, Tzu-Hsuan, et al.
Publicado: (2021)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

LAPTM4B Allele *2 Is Associated with Breast Cancer Susceptibility and Prognosis
por: Li, Xiaoyan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_585c5rbc6pqb3irseat1to4nfe